For the quarter ending 2026-03-31, ONMD had -$352K decrease in cash & cash equivalents over the period. -$1,544K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Stock warrant expense | - | 0 | 0 | 0 |
| Non-cash sepa commitment fee | - | 0 | - | - |
| Gain on forgiveness of ceba loan | - | 0 | 0 | - |
| Non-cash interest | - | 0 | 0 | 45 |
| Net loss | -2,453 | -3,140 | -741 | 1,080 |
| Gain on troubled debt restructurings | - | 0 | 1,862 | 3,707 |
| Depreciation and amortization | 11 | 9 | 10 | 46 |
| Loss on debt extinguishment | - | 0 | -41 | 0 |
| Stock-based compensation expense | 431 | 1,485 | 142 | 405 |
| Change in fair value of warrant liabilities | -16 | 33 | 20 | 3 |
| Change in fair value of pipe notes | - | - | 0 | -1,221 |
| Change in fair value of yorkville note | - | - | 0 | 64 |
| Change in fair value of convertible notes | - | 1,285 | - | - |
| Change in fair value of crypto assets bitcoin | 102 | -163 | 55 | -837 |
| Change in fair value of sepa derivative liabilities | 179 | 184 | -402 | 434 |
| Realized loss (gain) on sale of crypto assets bitcoin | -188 | 23 | 55 | 844 |
| Accounts receivable | 202 | -87 | 328 | 41 |
| Prepaid expenses and other current assets | -45 | 76 | -178 | -92 |
| Accounts payable and accrued expenses | 445 | 314 | 432 | -380 |
| Deferred revenues | 290 | -381 | 258 | -49 |
| Net cash used in operating activities | -1,542 | -1,713 | -1,558 | -4,232 |
| Purchases of property and equipment | 2 | 5 | 0 | 8 |
| Purchases of crypto assets bitcoin | - | 350 | 200 | 2,200 |
| Sales of crypto assets bitcoin | 354 | 304 | 1,308 | 3,458 |
| Proceeds from exercises of helena termination warrants | - | 60 | - | - |
| Net cash provided by investing activities | 352 | -51 | 1,108 | 1,250 |
| Proceeds from subscription agreements with related parties, net of issuance costs | - | - | 500 | 1,197 |
| Repayment of deferred underwriter fees | - | 0 | 500 | - |
| Repayment of yorkville note | - | 0 | 0 | 262 |
| Proceeds from line of credit borrowings | - | - | 0 | 0 |
| Repayment of shareholder loan | - | 0 | 0 | 0 |
| Repayment of line of credit borrowings | - | 0 | 0 | - |
| Repayment of deferred underwriter fees | - | - | -500 | 500 |
| Proceeds from issuance of shareholder loans | - | 0 | 0 | 0 |
| Proceeds from related party subscription agreements, net of issuance costs | - | 1,697 | - | - |
| Proceeds from issuance of yorkville note, net of issuance costs | - | 0 | - | - |
| Proceeds from yorkville sepa | 475 | 2,537 | 0 | 0 |
| Repayment of loan extensions | - | - | 12 | - |
| Repayment of loans payable | - | 401 | - | - |
| Proceeds from line of credit borrowings | - | 0 | - | - |
| Proceeds from subscription agreement | 500 | 0 | 0 | 2,497 |
| Repayment for common stock repurchase | - | - | 11 | - |
| Payment of issuance costs in connection with non-cash conversions of liabilities | - | 19 | - | - |
| Repayment of loans payable | 137 | 0 | 0 | 0 |
| Net cash provided by (used in) financing activities | 838 | 2,200 | 477 | 2,932 |
| Net increase in cash and cash equivalents | - | 436 | - | - |
| Net decrease in cash and cash equivalents | -352 | 436 | 27 | -50 |
| Cash and cash equivalents at beginning of period | 585 | 149 | 172 | - |
| Cash and cash equivalents at end of period | 233 | 585 | 149 | - |
OneMedNet Corp (ONMD)
OneMedNet Corp (ONMD)